Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic ...

31 July 2026 · By · Wire by Fusion42

Published

31 July 2026

Topic

regulatory

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at hmpgloballearningnetwork.com →

◆ Verified

Fusion42 · 31 July 2026 · Fusion42 review

The US FDA has granted Priority Review to a Biologics License Application for subcutaneous amivantamab, a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after platinum-based chemotherapy.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

The FDA has shown it will fast-track usability improvements, not just novel chemistry. If you can reformulate an existing therapy for a specific cancer population, you have a clear route to priority review.

◆ Coverage

1 source · 31 Jul 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfdaoncologydrug-discoverybiotechregulatory-pathway